Vanguard Group’s Alaunos Therapeutics TCRT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$97.1K Buy
30,061
+9,089
+43% +$29.4K ﹤0.01% 4181
2025
Q3
$51.2K Hold
20,972
﹤0.01% 4297
2025
Q2
$102K Hold
20,972
﹤0.01% 4148
2025
Q1
$30.4K Hold
20,972
﹤0.01% 4225
2024
Q4
$39.8K Sell
20,972
-24,376
-54% -$54.2K ﹤0.01% 4225
2024
Q3
$149K Sell
45,348
-17,567
-28% -$63.1K ﹤0.01% 4165
2024
Q2
$440K Hold
62,915
﹤0.01% 4043
2024
Q1
$1.14M Sell
62,915
-10
-0% -$200 ﹤0.01% 3767
2023
Q4
$667K Hold
62,925
﹤0.01% 3950
2023
Q3
$1.24M Buy
62,925
+2,180
+4% +$93.9K ﹤0.01% 3755
2023
Q2
$4.65M Sell
60,745
-293
-0.5% -$23.7K ﹤0.01% 3343
2023
Q1
$5.77M Buy
61,038
+53
+0.1% +$5.05K ﹤0.01% 3232
2022
Q4
$5.94M Sell
60,985
-98
-0.2% -$14.2K ﹤0.01% 3221
2022
Q3
$15.8M Sell
61,083
-889
-1% -$258K ﹤0.01% 2739
2022
Q2
$11.5M Sell
61,972
-9,886
-14% -$945K ﹤0.01% 2917
2022
Q1
$7.03M Sell
71,858
-5,700
-7% -$732K ﹤0.01% 3339
2021
Q4
$12.7M Sell
77,558
-5,014
-6% -$1.1M ﹤0.01% 3094
2021
Q3
$22.5M Sell
82,572
-22,611
-21% -$6.91M ﹤0.01% 2803
2021
Q2
$41.7M Sell
105,183
-1,800
-2% -$840K ﹤0.01% 2468
2021
Q1
$57.8M Buy
106,983
+520
+0.5% +$324K ﹤0.01% 2236
2020
Q4
$40.2M Buy
106,463
+4,573
+4% +$1.82M ﹤0.01% 2317
2020
Q3
$38.5M Sell
101,890
-1,341
-1% -$592K ﹤0.01% 2140
2020
Q2
$50.8M Buy
103,231
+2,189
+2% +$976K ﹤0.01% 2004
2020
Q1
$37.1M Buy
101,042
+17,075
+20% +$8.84M ﹤0.01% 2000
2019
Q4
$59.4M Buy
83,967
+9,485
+13% +$6.53M ﹤0.01% 2019
2019
Q3
$47.8M Sell
74,482
-550
-0.7% -$436K ﹤0.01% 2094
2019
Q2
$65.6M Buy
75,032
+7,787
+12% +$5.35M ﹤0.01% 1962
2019
Q1
$38.8M Buy
67,245
+30,025
+81% +$12.6M ﹤0.01% 2217
2018
Q4
$10.4M Sell
37,220
-21,338
-36% -$8.44M ﹤0.01% 2758
2018
Q3
$28.1M Buy
58,558
+1,296
+2% +$556K ﹤0.01% 2420
2018
Q2
$25.9M Buy
57,262
+1,061
+2% +$673K ﹤0.01% 2451
2018
Q1
$33M Sell
56,201
-415
-0.7% -$259K ﹤0.01% 2285
2017
Q4
$35.2M Buy
56,616
+2,035
+4% +$1.46M ﹤0.01% 2244
2017
Q3
$50.3M Buy
54,581
+2,151
+4% +$1.91M ﹤0.01% 2040
2017
Q2
$48.9M Buy
52,430
+3,693
+8% +$3.62M ﹤0.01% 2028
2017
Q1
$46.3M Buy
48,737
+2,645
+6% +$2.46M ﹤0.01% 2046
2016
Q4
$37M Buy
46,092
+1,298
+3% +$1.17M ﹤0.01% 2122
2016
Q3
$37.8M Sell
44,794
-48
-0.1% -$38.6K ﹤0.01% 2062
2016
Q2
$36.9M Buy
44,842
+1,029
+2% +$1.12M ﹤0.01% 2032
2016
Q1
$48.8M Buy
43,813
+1,210
+3% +$1.24M ﹤0.01% 1871
2015
Q4
$53.1M Buy
42,603
+13,169
+45% +$21.8M ﹤0.01% 1856
2015
Q3
$39.8M Buy
29,434
+1,364
+5% +$2.25M ﹤0.01% 1979
2015
Q2
$50.5M Buy
28,070
+7,133
+34% +$11.1M ﹤0.01% 1943
2015
Q1
$33.8M Buy
20,937
+2,790
+15% +$4.14M ﹤0.01% 2106
2014
Q4
$13.8M Buy
18,147
+224
+1% +$119K ﹤0.01% 2406
2014
Q3
$7.1M Sell
17,923
-1,117
-6% -$538K ﹤0.01% 2657
2014
Q2
$11.5M Buy
19,040
+2,114
+12% +$1.18M ﹤0.01% 2443
2014
Q1
$11.6M Buy
16,926
+726
+4% +$486K ﹤0.01% 2411
2013
Q4
$10.5M Buy
16,200
+2,415
+18% +$1.44M ﹤0.01% 2435
2013
Q3
$8.17M Buy
13,785
+1,576
+13% +$710K ﹤0.01% 2491
2013
Q2
$3.85M Buy
+12,209
New +$3.39M ﹤0.01% 2801

Other funds holding TCRT

Vanguard Group's TCRT Position: Q4 2025 in Review

Vanguard Group increased its Alaunos Therapeutics (TCRT) stake by 43% in Q4 2025, buying an estimated $29.4K and bringing the position to 30,061 shares worth $97.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4181.

Vanguard Group first reported a position in TCRT in Q2 2013 and has held it in 51 quarters since. The position peaked at $65.6M in Q2 2019. 27 funds tracked by Wall St. Rank hold TCRT as of Q4 2025.

  • Vanguard Group held 30,061 shares of Alaunos Therapeutics worth $97.1K as of Q4 2025.
  • Vanguard Group bought 9,089 Alaunos Therapeutics shares in Q4 2025, an estimated $29.4K.
  • Alaunos Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4181 holding.
  • Vanguard Group first reported a position in Alaunos Therapeutics in Q2 2013 and has held it in 51 quarters since.
  • Vanguard Group's Alaunos Therapeutics position peaked at $65.6M in Q2 2019.
  • 27 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.